Home›Daunorubicin Hydrochloride

Daunorubicin Hydrochloride

Also known as: Daunorubicin Hydrochloride

Route: Intravenous

Check Daunorubicin Hydrochloride Interactions →

3 interactions on record⛔ Black Box Warning

Daunorubicin Hydrochloride has 3 known drug interactions based on U.S. FDA drug labeling data. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Cyclophosphamide, Doxorubicin, Methotrexate. Patients taking Daunorubicin Hydrochloride should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 3
Major: 2
Moderate: 1

Major (2)

Daunorubicin Hydrochloride + Cyclophosphamide— Concurrent use may result in increased cardiotoxicity when used with daunorubicin hydrochloride.
Daunorubicin Hydrochloride + Doxorubicin— Previous doxorubicin use increases risk of cardiotoxicity with daunorubicin. Contraindicated if maximum cumulative doses…

Moderate (1)

Daunorubicin Hydrochloride + Methotrexate— High-dose methotrexate is hepatotoxic and may impair liver function, increasing risk of daunorubicin toxicity. Dosage re…

Daunorubicin Hydrochloride + Cyclophosphamide⚠️Major

Concurrent use may result in increased cardiotoxicity when used with daunorubicin hydrochloride.

Daunorubicin Hydrochloride + Doxorubicin⚠️Major

Previous doxorubicin use increases risk of cardiotoxicity with daunorubicin. Contraindicated if maximum cumulative doses previously received.

Daunorubicin Hydrochloride + Methotrexate🟡Moderate

High-dose methotrexate is hepatotoxic and may impair liver function, increasing risk of daunorubicin toxicity. Dosage reduction may be required.

⛔ FDA Black Box Warning

WARNINGS Daunorubicin hydrochloride injection must be given into a rapidly flowing intravenous infusion. It must never be given by the intramuscular or subcutaneous route. Severe local tissue necrosis will occur if there is extravasation during administration. Myocardial toxicity manifested in its most severe form by potentially fatal congestive heart failure may occur either during therapy or months to years after termination of therapy. The incidence of myocardial toxicity increases after a total cumulative dose exceeding 400 to 550 mg/m 2 in adults, 300 mg/m 2 in children more than 2 years of age, or 10 mg/kg in children less than 2 years of age. Severe myelosuppression occurs when used in therapeutic doses; this may lead to infection or hemorrhage. It is recommended that daunorubicin hydrochloride be administered only by physicians who are experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection. Dosage should be reduced in patients with impaired hepatic or renal function.

Contraindications

CONTRAINDICATIONS Daunorubicin hydrochloride is contraindicated in patients who have shown a hypersensitivity to it.

Pregnancy & Breastfeeding

Pregnancy Daunorubicin hydrochloride may cause fetal harm when administered to a pregnant woman. An increased incidence of fetal abnormalities (parieto-occipital cranioschisis, umbilical hernias, or rachischisis) and abortions was reported in rabbits at doses of 0.05 mg/kg/day or approximately 1/100th of the highest recommended human dose on a body surface area basis. Rats showed an increased incidence of esophageal, cardiovascular and urogenital abnormalities as well as rib fusions at doses of 4 mg/kg/day or approximately 1/2 the human dose on a body surface area basis. Decreases in fetal birth weight and post-delivery growth rate were observed in mice. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.